LIVIVO - Search results -

Search results

Result 1 - 10 of total 65

Search options

Article: Retreatment with Immune Checkpoint Inhibitors in the New Scenario of Immunotherapy in Non-Small Cell Lung Cancer.

Rossi, Sabrina / Masini, Silvia / Finocchiaro, Giovanna / Lorenzi, Elena / Toschi, Luca / Santoro, Armando

2024 Volume 16, Issue 9

Abstract: The advent of immunotherapy has transformed the treatment paradigm for metastatic non-small cell lung cancer (NSCLC). In the past few years, several studies have investigated the potential role of immune checkpoint inhibitors (ICIs) in resectable and ... ...

Abstract	The advent of immunotherapy has transformed the treatment paradigm for metastatic non-small cell lung cancer (NSCLC). In the past few years, several studies have investigated the potential role of immune checkpoint inhibitors (ICIs) in resectable and unresectable locally advanced disease, achieving remarkable results that led to their approval in clinical practice. However, there is limited evidence on immunotherapy rechallenge after recurrence, with the majority of available knowledge coming from retrospective studies which involve heavily pretreated patients with advanced NSCLC. The recent introduction in the curative setting and the potential regulatory restrictions raise questions about the optimal choice of first-line and subsequent therapies for patients with systemic relapse. The role of immunotherapy readministration in this new scenario needs to be clarified, as well as the identification of patients for whom it is more appropriate, including clinical characteristics, duration of response, switching to other ICIs, reasons for discontinuation and immune-related toxicity. Here, we review literature on rechallenge with immunotherapy, including efficacy, safety profile and potential predictive factors of response.
Language	English
Publishing date	2024-04-26
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers16091683
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors.

Castello, Angelo / Rossi, Sabrina / Toschi, Luca / Lopci, Egesta

Journal of clinical medicine

2021 Volume 10, Issue 6

Abstract: Introduction: In the current study, we aimed to assess the impact of antibiotics (ATB) and metabolic parameters on clinical outcome of non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI).: Methods: Data from ...

Abstract	Introduction: In the current study, we aimed to assess the impact of antibiotics (ATB) and metabolic parameters on clinical outcome of non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI). Methods: Data from fifty NSCLC patients referred for ICI between December 2015 and May 2019 were analyzed. All patients underwent 18F-fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG PET/CT) and contrast-enhanced CT at baseline and for response assessment after 6-8 weeks. Patients who received ATB within 1 month before or after the first dose of ICI were compared with those who did not. Response assessment according to iRECIST and EORTC was evaluated, as well as progression-free survival (PFS) and overall survival (OS). For semi-quantitative parameters, we computed metabolic tumor volume (MTV), total lesion glycolysis (TLG) and their variations (∆). Results: Twenty NSCLC cases of 50 (40%) had received ATB. Patients receiving ATB had a higher number of metastases ( Conclusions: ATB therapy seems to be associated with a worse treatment response, PFS, and higher metabolic tumor burden in NSCLC patients treated with ICI.
Language	English
Publishing date	2021-03-17
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm10061251
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1.

Castello, Angelo / Rossi, Sabrina / Toschi, Luca / Lopci, Egesta

Frontiers in oncology

2020 Volume 10, Page(s) 1090

Abstract: Introduction/Aim: ...

Abstract	Introduction/Aim:
Language	English
Publishing date	2020-07-31
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2020.01090
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer.

Rossi, Sabrina / Toschi, Luca / Finocchiaro, Giovanna / Santoro, Armando

Immunotherapy

2020 Volume 12, Issue 10, Page(s) 715–724

Abstract: Aim: ...

Abstract	Aim:
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Female ; Humans ; Lung Neoplasms/diagnosis ; Lung Neoplasms/drug therapy ; Lymphocyte Count ; Lymphocytes/pathology ; Male ; Middle Aged ; Neutrophils/pathology ; Nivolumab/therapeutic use ; Prognosis ; Retrospective Studies ; Treatment Outcome
Chemical Substances	Antineoplastic Agents ; Nivolumab (31YO63LBSN)
Language	English
Publishing date	2020-06-11
Publishing country	England
Document type	Journal Article
ISSN	1750-7448
ISSN (online)	1750-7448
DOI	10.2217/imt-2019-0154
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article: The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?

Rossi, Sabrina / Pagliaro, Arianna / Michelini, Angelica / Navarria, Pierina / Clerici, Elena / Franceschini, Davide / Toschi, Luca / Finocchiaro, Giovanna / Scorsetti, Marta / Santoro, Armando

Cancers

2023 Volume 15, Issue 24

Abstract: Small-cell lung cancer is an extremely chemo-sensitive disease; the addition of immunotherapy to chemotherapy has demonstrated a slight clinical benefit in pivotal trials, even with a statistically significant difference in terms of survival outcomes ... ...

Abstract	Small-cell lung cancer is an extremely chemo-sensitive disease; the addition of immunotherapy to chemotherapy has demonstrated a slight clinical benefit in pivotal trials, even with a statistically significant difference in terms of survival outcomes when compared to chemotherapy alone. In this scenario, the role of radiotherapy as a consolidation treatment in thoracic disease or as a prophylactic therapy in the brain should be clarified. In addition, due to the frailty and the poor prognostic characteristics of these patients, the need for predictive biomarkers that could support the use of immunotherapy is crucial. PD-L1 and TMB are not actually considered definitive biomarkers due to the heterogeneity of results in the literature. A new molecular classification of small-cell lung cancer based on the expression of key transcription factors seems to clarify the disease behavior, but the knowledge of this molecular subtype is still insufficient and the application in clinical practice far from reality; this classification could lead to a better understanding of SCLC disease and could provide the right direction for more personalized treatment. The aim of this review is to investigate the current knowledge in this field, evaluating whether there are predictive biomarkers and clinical patient characteristics that could help us to identify those patients who are more likely to respond to immunotherapy.
Language	English
Publishing date	2023-12-08
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers15245761
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience.

Rossi, Sabrina / Finocchiaro, Giovanna / Toschi, Luca / Santoro, Armando

Immunotherapy

2019 Volume 11, Issue 11, Page(s) 945–952

Abstract: Aim: ...

Abstract	Aim:
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Brain Neoplasms/drug therapy ; Brain Neoplasms/mortality ; Brain Neoplasms/pathology ; Brain Neoplasms/secondary ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease-Free Survival ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Metastasis ; Nivolumab/administration & dosage ; Retrospective Studies ; Survival Rate
Chemical Substances	Nivolumab (31YO63LBSN)
Language	English
Publishing date	2019-06-14
Publishing country	England
Document type	Clinical Trial ; Journal Article
ISSN	1750-7448
ISSN (online)	1750-7448
DOI	10.2217/imt-2019-0029
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Response to first-line pembrolizumab in metastatic

Rossi, Sabrina / Pagliaro, Arianna / Finocchiaro, Giovanna / Marinello, Arianna / Giordano, Laura / Bria, Emilio / Stefani, Alessio / Vitale, Antonio / Toschi, Luca / D'Argento, Ettore / Santoro, Armando

Future oncology (London, England)

2024 Volume 20, Issue 7, Page(s) 373–380

Abstract: Aims: ...

Abstract	Aims:
MeSH term(s)	Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Proto-Oncogene Proteins p21(ras)/genetics ; Retrospective Studies ; Antibodies, Monoclonal, Humanized
Chemical Substances	pembrolizumab (DPT0O3T46P) ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2) ; KRAS protein, human ; Antibodies, Monoclonal, Humanized
Language	English
Publishing date	2024-03-06
Publishing country	England
Document type	Journal Article
ZDB-ID	2274956-1
ISSN	1744-8301 ; 1479-6694
ISSN (online)	1744-8301
ISSN	1479-6694
DOI	10.2217/fon-2023-0952
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6478: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters.

Castello, Angelo / Rossi, Sabrina / Toschi, Luca / Mansi, Luigi / Lopci, Egesta

Cancers

2020 Volume 12, Issue 6

Abstract: We investigated the role of soluble PD-L1 (sPD-L1) in non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI) and analyzed its association with clinical outcomes and metabolic parameters by 18F-fluorodeoxyglucose ... ...

Abstract	We investigated the role of soluble PD-L1 (sPD-L1) in non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI) and analyzed its association with clinical outcomes and metabolic parameters by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT). Between July 2017 and May 2019, we enrolled 20 candidate patients of ICI therapy who had serum frozen samples and 18F-FDG PET/CT available, both at baseline and at the first response evaluation. This analysis is embedded into a larger prospective study (NCT03563482). Twelve out of 20 patients received nivolumab, one patient received combination of nivolumab and ipilimumab, whereas the others received pembrolizumab. Median sPD-L1 level at baseline was 27.22 pg/mL. We found a significant association between patients with elevated sPD-L1, above the median value, and high metabolic tumor burden, expressed by metabolic tumor volume (MTV, 115.3 vs. 35.5,
Language	English
Publishing date	2020-05-27
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers12061373
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.

Castello, Angelo / Toschi, Luca / Rossi, Sabrina / Mazziotti, Emanuela / Lopci, Egesta

Journal of cancer research and clinical oncology

2020 Volume 146, Issue 5, Page(s) 1235–1243

Abstract: Purpose: This prospective study evaluated whether peripheral blood biomarkers and metabolic parameters on F-18 fludeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) could be associated with clinical outcome in non-small cell ...

Abstract	Purpose: This prospective study evaluated whether peripheral blood biomarkers and metabolic parameters on F-18 fludeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) could be associated with clinical outcome in non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI). Methods: Data from 33 patients with NSCLC and treated with ICI were collected. Complete blood cell counts before and at the first restaging were measured. All patients underwent F-18 FDG PET/CT at baseline, while 25 patients at the first restaging. Progression-free survival (PFS) and overall survival (OS) were determined and compared using the Kaplan-Meier and the log-rank test. The median follow-up was 11.3 months (range 1-17 months). Results: Multivariate analyses demonstrated that low neutrophil-to-lymphocyte ratio (NLR < 4.9) and low total lesion glycolysis (TLG < 541.5 ml) at the first restaging were significantly associated with PFS (both p = 0.019) and OS (p = 0.001 and p = 0.048, respectively). An immune-metabolic-prognostic index (IMPI), based on post-NLR and post-TLG was developed, categorizing 3 groups: high risk, 2 factors; intermediate risk, 1 factor; low risk, 0 factors. Median PFS for low, intermediate and high risk was 7.8 months (95% CI 4.6-11.0), 5.6 months (95% CI 3.8-7.4), and 1.8 months (95% CI 1.6-2.0) (p < 0.001) respectively. Likewise, median OS was 15.2 months (95% CI 10.9-19.6), 13.2 months (95% CI 5.9-20.3), and 2.8 months (95% CI 1.4-4.2) (p < 0.001), respectively. Conclusion: IMPI at the first restaging, combining both inflammatory and metabolic biomarkers, was correlated with PFS and OS. IMPI can be a potentially valuable tool for identifying NSCLC patients who are likely to benefit from ICI.
MeSH term(s)	Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Agents, Immunological/administration & dosage ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/biosynthesis ; B7-H1 Antigen/immunology ; Biomarkers, Tumor/blood ; Carcinoma, Non-Small-Cell Lung/blood ; Carcinoma, Non-Small-Cell Lung/diagnostic imaging ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/immunology ; Female ; Fluorodeoxyglucose F18 ; Humans ; Lung Neoplasms/blood ; Lung Neoplasms/diagnostic imaging ; Lung Neoplasms/drug therapy ; Lung Neoplasms/immunology ; Male ; Middle Aged ; Nivolumab/administration & dosage ; Positron Emission Tomography Computed Tomography ; Prognosis ; Prospective Studies ; Radiopharmaceuticals ; Survival Rate
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; B7-H1 Antigen ; Biomarkers, Tumor ; CD274 protein, human ; Radiopharmaceuticals ; Fluorodeoxyglucose F18 (0Z5B2CJX4D) ; Nivolumab (31YO63LBSN) ; pembrolizumab (DPT0O3T46P)
Language	English
Publishing date	2020-02-11
Publishing country	Germany
Document type	Journal Article
ZDB-ID	134792-5
ISSN	1432-1335 ; 0171-5216 ; 0084-5353 ; 0943-9382
ISSN (online)	1432-1335
ISSN	0171-5216 ; 0084-5353 ; 0943-9382
DOI	10.1007/s00432-020-03150-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity.

Rossi, Sabrina / Castello, Angelo / Toschi, Luca / Lopci, Egesta

Immunotherapy

2018 Volume 10, Issue 9, Page(s) 797–805

Abstract: The treatment algorithm of advanced non-small-cell lung cancer is rapidly evolving. This result is mostly related to the availability in clinical practice of checkpoint inhibitors targeting the programmed death-1 (PD-1) and its ligands (PD-Ls) ... ...

Abstract	The treatment algorithm of advanced non-small-cell lung cancer is rapidly evolving. This result is mostly related to the availability in clinical practice of checkpoint inhibitors targeting the programmed death-1 (PD-1) and its ligands (PD-Ls) immunosuppressive pathway. Although patient's selection in the first-line setting relies essentially on high levels of PD-L1 tumor expression, treatment choice in pretreated patients is more challenging and, although clinical and biological characteristics might be of help, there is an urgent need for novel tools to better identify sensitive and resistant patients. In this context, the integration of molecular markers and immune-PET imaging might represent a potentially effective strategy to refine patient selection.
MeSH term(s)	Antibodies, Monoclonal/therapeutic use ; B7-H1 Antigen/immunology ; Biomarkers, Tumor/metabolism ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/therapy ; Clinical Trials as Topic ; Humans ; Immunotherapy/methods ; Lung Neoplasms/diagnosis ; Lung Neoplasms/immunology ; Lung Neoplasms/therapy ; Patient Selection ; Prognosis ; Programmed Cell Death 1 Receptor/immunology ; Treatment Outcome
Chemical Substances	Antibodies, Monoclonal ; B7-H1 Antigen ; Biomarkers, Tumor ; CD274 protein, human ; Programmed Cell Death 1 Receptor
Language	English
Publishing date	2018-07-16
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ISSN	1750-7448
ISSN (online)	1750-7448
DOI	10.2217/imt-2017-0187
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED